NAD IV vs. NR and NMN: What Human Trials Really Show

What is actually for sale at the IV clinic is not a molecule. It is the hope that the tiredness has a single switch—that a coenzyme the body already makes, dripped slowly into a vein, might hand back the mornings. The fear underneath is older than the branding: that the energy leaving is the life leaving.

Hold that hope against the record and the record is thin. The most cited direct-IV experiment gave eight healthy men 750 milligrams of NAD+ over six hours and mapped where the dose appeared to go; it tested no fatigue, cognition, function, or lifespan. A later commercial-clinic chart review recorded moderate-to-severe gastrointestinal symptoms, increased heart rate, and chest pressure during NAD+ infusions—symptoms that ended when the infusion stopped. An August YouTube conversation between physician Kevin White and geroscientist Matt Kaeberlein pressed the same uncomfortable question: is a higher NAD reading even the outcome that matters?

That distinction changes the verdict. Direct IV NAD, oral nicotinamide riboside (NR), and oral nicotinamide mononucleotide (NMN) are not interchangeable delivery systems for one proven treatment; they enter the body differently and cannot borrow one another's results. The most defensible summary in 2026: oral NR and NMN reliably engage the biochemical target, IV NAD has a much thinner evidence base, and neither has shown that a healthy person lives longer.

A necessary molecule is not automatically a therapy

NAD+ and its reduced partner NADH shuttle electrons through reactions that help cells extract energy from food. NAD+ is also consumed by enzymes involved in DNA repair, signaling and stress responses, including PARPs, sirtuins and CD38. Those roles make NAD biology important. They do not make every attempt to increase NAD clinically useful.

Even the premise that NAD universally declines with age needs a tissue label. A critical review found that much of the decline literature was limited to particular tissues, cells or methods, with especially sparse human evidence. Then a 2026 Nature Metabolism study measured whole-blood NAD+ across seven independent human cohorts and found it stable with age and lifestyle interventions, although it rose after NR supplementation. Whole blood cannot settle what happens inside muscle, liver or brain. It can, however, puncture the idea that one low, body-wide NAD tank explains normal aging—or that a blood number is a validated personal aging score.

What an IV actually proved

The most cited direct-IV experiment was a 2019 pharmacokinetic pilot, not an anti-aging trial. Eight healthy men received 750 milligrams of NAD+ over six hours; three controls received saline. Investigators tracked the molecule and its breakdown products in plasma and urine. Measured plasma NAD+ and metabolites did not rise during the first two hours, consistent with rapid uptake, metabolism or movement out of the sampled compartment. By six hours, plasma and urinary measures had changed. The study did not test fatigue, cognition, physical function, disease events, biological age or lifespan. It mapped where a dose appeared to go.

A 2026 commercial-clinic chart review added tolerability data, but not a convincing benefit test. Six clients received 500 milligrams of IV NAD+ on four consecutive days, while eight received IV NR. There was no placebo, random assignment or blinded outcome assessment. All six NAD+ clients reported moderate-to-severe gastrointestinal symptoms during infusion, along with symptoms that included increased heart rate and chest pressure; the symptoms ended when the infusion stopped. The NAD+ sessions averaged 97 minutes, versus 37 for IV NR. A few laboratory values changed over 30 days, but the groups were tiny, baseline characteristics differed and lifestyle was not controlled. Every author worked for the clinic chain that provided the therapy.

The broadest recent synthesis is more decisive than either pilot. A 2026 systematic review found 33 human NAD-related intervention studies, including 28 randomized trials. It found no eligible outcomes trial of direct IV or intramuscular NAD for anti-aging or wellness. The 2019 infusion study counted only as pharmacokinetic context. That leaves direct IV NAD at biochemical plausibility and short-term observation—not demonstrated healthspan benefit.

Oral precursors have more data—and a smaller promise

Oral NR and NMN have the stronger human case, but “stronger” is relative. Across trials they repeatedly increase NAD-related metabolites in blood and sometimes muscle. That is target engagement: evidence that the compound reaches and changes the intended pathway. It is not proof that the change improves how long or well people live.

Consider NR. In 24 healthy middle-aged and older adults, six weeks of NR increased NAD-related measures and produced preliminary vascular signals. In 12 older men, 21 days changed the muscle NAD metabolome and inflammatory and transcriptional signatures but did not improve mitochondrial bioenergetics. In 13 adults with overweight or obesity, six weeks changed muscle metabolites and a few body-composition measures, yet did not improve insulin sensitivity, mitochondrial function, ectopic fat, ambulatory blood pressure, cardiac measures or inflammation.

The gap appears again in brain and symptom studies. A 10-week pilot in 20 older adults with mild cognitive impairment raised blood NAD+ 2.6-fold but did not change cognition. A 2025 trial in 58 people with long COVID raised NAD+ roughly 2.6- to 3.1-fold, yet found no significant advantage over placebo for cognition, fatigue, sleep, anxiety or depression. Attrition was substantial, and the study had industry support and author equity disclosures. These findings do not prove NR is useless; they show why a moved biomarker cannot stand in for a patient-important result.

NMN has generated selected positive signals. A small 10-week trial in postmenopausal women with prediabetes and overweight or obesity improved clamp-measured muscle insulin sensitivity. That is a meaningful physiological endpoint in a defined population, not evidence of general rejuvenation. Other small trials have reported secondary walking or sleep findings, often amid null primary outcomes. The 2026 systematic review's overall judgment was therefore appropriately restrained: oral NR and NMN were generally tolerated for weeks to months and consistently changed biochemistry, while functional, metabolic and vascular outcomes were mixed, endpoint-specific or null.

The route adds risks the pathway diagram cannot show

Short oral trials cannot answer questions about years of use, rare harms, cancer risk or interactions in medically complex people. IV delivery adds the risks of venous access and sterile compounding, plus route-specific infusion reactions. In an October 2024 notice, the FDA warned compounders that food-grade NAD+ is not suitable for making sterile drugs without appropriate processing and described adverse-event reports consistent with excessive endotoxin exposure.

A January 20, 2026 FDA warning letter provides a verified example of the product-quality problem: an unopened vial from an implicated compounded NAD+ lot contained excessive bacterial endotoxin. That record supports concern about one facility and lot; it does not establish how often contamination occurs or prove that every reaction to NAD+ has the same cause. It does show why “naturally present in the body” says nothing about an injectable product's sterility.

Regulatory vocabulary can mislead, too. A compounded preparation is not thereby FDA-approved for anti-aging. The agency's April 2026 503A list placed NAD among substances under evaluation, while its January warning letter discussed separate 503B requirements. Neither status supplies efficacy evidence. A prescription, clinic setting or white coat cannot substitute for a randomized trial.

The trial that would change the answer

A persuasive longevity study would begin with a defined population and route, then randomize enough participants to IV NAD, a credible placebo or an oral comparator. It would prespecify a functional or clinical outcome—walking ability, validated fatigue or cognition, disease events—not merely blood NAD. It would track infusion reactions, product testing, dropouts and costs, follow participants long enough to test durability, and disclose commercial ties. An actual lifespan trial may be impractical, but the present evidence has not yet cleared the nearer healthspan bar.

For now, the sharpest buying question is not “Does NAD matter?” It plainly does. Ask whether the exact product, route and population have shown a benefit worth the burden and risk. For IV NAD sold to generally healthy adults, that evidence is absent. Oral NR and NMN have a more credible target-engagement record and a handful of population-specific signals, but no proof of broad anti-aging effects, prevention of major age-related disease or longer life. Biology made NAD interesting. Only outcomes can make it a treatment. Educational, not medical advice.